WithdrawnPhase 1NCT02528877
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis
Studying Therapy related acute myeloid leukemia and myelodysplastic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- City of Hope Medical Center
- Principal Investigator
- Haris Ali, M.DCity of Hope Medical Center
- Intervention
- Allogeneic Bone Marrow Transplantation(procedure)
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2015
Study locations (1)
- City of Hope Medical Center, Duarte, California, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02528877 on ClinicalTrials.gov